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A new system for conditional approval of regenerative medicine products will allow products of undeter-
mined efficacy to enter the Japanese market. The potential scientific, economic, and ethical implications
of this program highlight the need for further discussion and refinement.Introduction
Last year, Japan introduced sweeping
changes to its regulation of ‘‘regenerative
medicine’’ therapeutics, a novel product
classification that includes a range of
human cell- and tissue-based biologics.
The reforms were greeted with intense
international interest, but detailed infor-
mation in English has been scarce—a
deficit that the Forum by Konomi in this
issue goes some way to address (Konomi
et al., 2015). While many aspects of the
new laws governing cell-based products
and medical procedures are straightfor-
ward and welcome, perhaps the most
prominent change—the introduction of
a new system providing for conditional,
limited-term market authorization of
regenerative medicine products—calls
for closer scrutiny and critical analysis,
as it dramatically relaxes the requirement
to demonstrate the clinical utility of such
products prior to marketing.
Under the terms of the amended
Pharmaceuticals, Medical Devices and
Other Therapeutic Products Act, clinical
trial sponsors now have the option to
seek market approval for up to 7 years
for regenerative medicine products for
which data from early phase trials demon-
strate safety and are ‘‘likely to predict
efficacy.’’ Moreover, such conditionally
approved products will be eligible for
reimbursement in Japan’s copayment-
based universal health insurance system,
in which payers and individuals seeking
treatment typically split costs 70:30.
Proponents claim that these changes will
help speed patient access and provide a
much-needed source of revenue for com-
panies confronting the ‘‘Valley of Death’’
between early-stage clinical trials and
full market authorization. However, there
has been little public discussion of thesereforms in the international community,
presumably due in part to the paucity
of detailed information in English on
the new system, although the Phar-
maceuticals and Medical Devices Agency
(PMDA) has provided useful summaries
on its website (e.g., Konomi et al., 2015).
In this Forum, using Japanese-
language source materials, I analyze the
conditional approvals system in terms
of its potential impact on the stem cell
field, the Japanese market, and patient
welfare, and I suggest a number of
refinements that may help this ambitious
measure achieve its goals.
Background
A key moment in the early history of the
new law came with the 2012 ‘‘Yokohama
Declaration’’ by the Japanese Society
for Regenerative Medicine (JSRM), which
called for ‘‘revisiting the evaluation of effi-
cacy of regenerative medicine products
(including, under some conditions, study
designs other than randomized controlled
trials)’’ and plans for ‘‘early approvals
with an emphasis on post-market clinical
evaluations’’ (http://www.asas.or.jp/jsrm/
announcements/120613.html). This shift
toward post-hoc efficacy testing repre-
sented a significant break from previous
statements by the society calling for
more and better regulatory oversight
(http://www.asas.or.jp/jsrm/announcements/
100407.html) toward market-based
schemessimilar to those that have recently
been promulgated by free-market advo-
cacy groups in the United States and other
countries (Bianco and Sipp, 2014).
The conditional approval system for
regenerative medicine was enacted with
the stated goal of promoting patient ac-
cess and commercial development, but
it was also justified by a number of otherCell Stem Cerationales. Since the conditional approval
system’s apparent formulation in the
Yokohama Declaration, emphasis has
been placed on the notion that it will be
‘‘difficult to demonstrate the efficacy’’
of human cell-based biologics due to
their ‘‘distinct properties’’ (http://www.
asas.or.jp/jsrm/announcements/120613.
html), language that is echoed inmaterials
explaining the conditional approvals sys-
tem issued by both the PMDA and the
Ministry of Health, Labour and Welfare
(MHLW). This brings the presumptive
function for the conditional approvals
pathway into clearer focus: it seems in-
tended not only to accelerate access
and support industry, but to shift the
determination of efficacy from premarket
clinical trials to a (yet-undefined) post-
market mechanism.
Despite the acknowledged uncertainty
about the efficacy of conditionally
approved regenerative medicine prod-
ucts, the Central Social Insurance Medi-
cal Council (Chuikyo), which sets reim-
bursement policy for approved medical
products in Japan, agreed tomake condi-
tionally approved regenerative medicine
products reimbursable, although some
concerns were raised about the current
costs of investigational interventions,
which were estimated to run to 10 million
yen (83,000 USD) during hearings prior
to the decision (https://www.m3.com/
open/iryoIshin/article/263285/). It should
be noted that the practice of allowing
products to enter the Japanese market
without substantial efficacy data is not
a new phenomenon. In the 1970s and
1980s, for example, Japan saw numerous
highly profitable oncology drugs of
disputable clinical benefit flood the mar-
ket (Fukushima, 1989). This tide of ‘‘inef-
fectives’’ (Thomas, 2001) was stemmedll 16, April 2, 2015 ª2015 Elsevier Inc. 353
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ference on Harmonization of Technical
Requirements for Registration of Pharma-
ceuticals for Human Use (ICH) in 1990
(Umemura, 2011). Ironically, the new
conditional approval system for regenera-
tive medicine products represents a
break from such harmonization, notwith-
standing comparisons to more focused
programs such as the FDA’s break-
through designation system, which are
not designed to promote a single product
category and which do not extend to such
a broad gamut of indications (in the Japa-
nese act these include but are not limited
to neglected, ‘‘serious,’’ and life-threat-
ening diseases). This open-ended
approach may leave Japan with a new
set of medical products unrecognized by
other countries due to efficacy concerns.
The experience in Korea, which trig-
gered alarm in Japan when it approved
three stem cell products—drawing to an
apparent lead at a time when Japan did
not have a single stem cell-based candi-
date in the pipeline—provides an inter-
esting counterpoint to the new Japanese
measures. As of the time of publication,
however, none of the three stem cell bio-
logics approved by the Korean Food &
Drug Administration (KFDA; re-desig-
nated as Ministry of Food and Drug
Safety in March 2013) were deemed reim-
bursable under the national healthcare
insurance system in that country due to
insufficiently compelling efficacy data,
leaving people to pay all costs out of
pocket. Interestingly, in 2012 a proposal
was raised in the Korean National Assem-
bly to provide for authorization of stem
cell therapeutics based solely on phase I
data or investigator-led studies; however,
according to one commentator, the
proposal was opposed by the domestic
industry, as companies were ‘‘concerned
about the possible decline of the credi-
bility of their cell therapy products in
international and domestic markets under
such conditions’’ (Oh, 2012).
A second feature of the raft of regulatory
reforms enacted in 2014 interestingly
appears to target the exploitation of
Japan’s broad latitude for private medical
practice by self-described ‘‘stem cell ther-
apy’’ clinics, exemplified by the case of a
Korean company that established treat-
ment centers in Kyoto, Tokyo, and Fu-
kuoka (Sakagami, 2013). The new ‘‘Act
on the Safety of Regenerative Medicine’’354 Cell Stem Cell 16, April 2, 2015 ª2015 Elcomplements the amended ‘‘Pharmaceu-
ticals, Medical Devices and Other Thera-
peutic Products Act’’ by introducing a
risk-based registration and approvals pro-
cess for theuseof cell-based interventions
byprivatephysicianswhodonotdistribute
products or seek reimbursement, thereby
avoiding regulation by the PMDA. The
new law wisely places certain cell types,
such as pluripotent stem cells, in the high-
est risk tier, and requires safety review and
approval by the MHLW prior to the clinical
use of such interventions. Lower risk tiers,
which include somatic stem cells and
other somatic cells, require only review
by external committee and notification
of the treatment plan to the MHLW.
These measures may help limit the un-
regulated marketing of unproven stem
cell-based interventions as medical prac-
tice, which the JSRM previously worried
would make Japan a ‘‘therapeutic haven’’
for predatory foreign firms (http://www.
asas.or.jp/jsrm/announcements/110201.
html).
Implications
As things now stand, the conditional
approvals system for regenerative medi-
cine products in Japan may be used to
market products of unknown efficacy, to
be paid for through a combination of
healthcare insurance and patient out-of-
pocket expenses. Any such system,
unless closely supervised and strictly
delimited, has potential for abuse and
unintended consequences. Unfortunately,
the PMDA, Japan’s medical product
regulatory agency, is significantly under-
resourced and underpowered compared
to countries at similar levels of develop-
ment, and although this situation has
been improving in recent years, the agency
asawhole employs only around1,000staff
(Konomi et al., 2015), fewer people than
the single division of the FDA dedicated
to overseeing biologics, and well less
than 10% of the FDA total (http://www.
fda.gov/downloads/AboutFDA/Reports
ManualsForms/Reports/BudgetReports/
UCM388309.pdf). The JSRM has been
working to fill the void, introducing a certifi-
cation system for regenerative medicine
specialists, but what role, if any, such spe-
cialistswill play inmarket oversight or advi-
sory capacities remains unclear.
The central question that will need to be
addressed, and quickly, is, how will effi-
cacy be evaluated during the conditionalsevier Inc.approval period? Surprisingly, this has
yet to be fully explicated, even now that
the new system has become the law of
the land. The difficulties in testing prod-
ucts in randomized clinical trials on a
post-market basis are well known. Few
subjects will choose to enter a trial if
they already have access to the agent,
and there is a significant risk of biasing in-
clusion/exclusion and outcome evalua-
tion if access is influenced by ability to
pay (the high estimated prices for regen-
erative medicine products may put them
out of reach of low-income subjects,
even with insurance), or the act of paying
itself. Whether evaluation of efficacy for
conditionally approved products under
the new Japanese system will be through
consultation with relevant medical spe-
cialties, centralized outcome reporting,
or some other measure has not been
made public, but it will be an enormous
challenge to identify an approach that is
as reliable and free of subjective bias as
the randomized clinical trial. The lack of
an explicit plan for determining efficacy
during the conditional approval period
points to a strong underlying assumption
that regenerative medicine products will
ultimately prove efficacious. However, all
indications from more mature and bet-
ter-funded areas of clinical development
suggest that such optimism may be
misplaced; clinical attrition for many
medical product categories approaches
90% (Hay et al., 2014).
A second set of questions surrounds
the claim that products will be approved
only after a demonstration of safety. Data
from phase I clinical trials clearly do not
provide conclusive evidence of safety,
only evidence suggesting that the inves-
tigational product is sufficiently well
tolerated to proceed to phase II, even
for rapidly metabolized products such
as small-molecule drugs. For regene-
rative medicine products composed of
living cells intended to integrate into
host tissue, adverse events may show
extraordinarily long latencies (Dlouhy
et al., 2014). Although the original ratio-
nale for the conditional approvals system
focused on the difficulties of assessing
efficacy in cell-based products, it should
not be forgotten that long-term safety
remains a major unresolved issue, which
should give us pause when considering
the potential for rapid uptake of a con-
ditionally approved product targeting a
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consequence, the potential exposure of
large numbers of people to long-term
risk.
In terms of economic impact, there is
indisputably increased revenue potential
for companies seeking to develop regen-
erativemedicine products. However, it re-
mains to be seen whether allowing prod-
ucts of under-determined effectiveness
to enter the Japanese market will benefit
the country as a whole. On the face of it,
paying large sums for medical products
lacking solid evidence of efficacy is a
losing proposition (https://www.m3.com/
open/iryoIshin/article/263285/). Money
so spent might otherwise be used to pay
for other interventions, or invested in
more traditional R&D projects. But condi-
tional approval will have other economic
effects as well. By limiting the conditional
approval pathway only to regenerative
medicine products, the government intro-
duces a disincentive to invest in other
areas of medical product development
with less accommodating market access
pathways. This may lead to inferior cell-
based products being rewarded at the
expense of superior alternative modal-
ities. Preferential treatment tilts the level
playing field that uniform approval path-
ways are designed to maintain.
Likewise, uncertainty about efficacy will
make price-setting decisions particularly
difficult. While prices for drug products
are set centrally in Japan, these are typi-
cally based on the knowledge that such
products have demonstrated safety and
efficacy. What is the appropriate price
for a medical product when it is unclear
whether it works when used as directed?
Along the same lines, labeling will need
to be handled delicately, given the lack
of definitive efficacy data for any specific
indication, which secondarily raises the
question of whether to permit off-label
uses. The balancing of risks and benefits,
based on advance knowledge, is a
cornerstone in the structure of regulated
healthcare markets. By weakening the
requirement to show clinical benefit
before market entry, systems such as
conditional approval threaten to under-
mine the entire edifice.
At the international level, the conse-
quences from Japan’s adoption of condi-
tional approvals may be profound. Given
the current regulatory regimes in other
major healthcare markets, it seems un-likely that conditionally approved prod-
ucts will be marketable in other countries.
(Indeed, this has been the experience for
Korea’s stem cell biologics.) Although
the ICH has so far little to say on cell
biologics, the introduction of a pathway
inconsistent with those in other countries
is clearly a move away from cross-border
standardization. Moreover, the govern-
ment has indicated that regenerative
medicine products developed by non-
Japanese firms will also be eligible to
apply for conditional approval, which
could result in Japan’s taxpayers and
healthcare patients underwriting a foreign
company’s product development.
The ethical implications of attenuating
the risk:benefit clinical knowledge base
are also significant. Clinical trial sponsors
are traditionally required to cover the
costs of the investigation for good rea-
sons. People receiving investigational
interventions, including those that have
been conditionally approved, inevitably
take on some degree of physical risk,
due to the uncertain nature of the safety,
not to mention the opportunity risks,
involved in choosing one treatment option
over another.
Recommendations
The new Japanese legislation represents
a bold and well-intended experiment,
but one that I would argue has not
been considered and fleshed out in
the needed detail. In order to protect
patients and maximize the chances that
conditional approval will benefit both the
regenerative medicine industry and the
Japanese healthcare system, a number
of refinements should be made. First,
and most importantly, people seeking
treatment should not be required to pay
to receive conditionally approved prod-
ucts. The conditional period is essentially
an unorthodox test of product efficacy, in
which people are already assuming signif-
icant risks for indeterminate benefit. To
prevent a situation in which individuals,
many of them presumably suffering from
serious illnesses, are required to pay
to serve as test subjects in post-market
experiments conducted in the service
of for-profit companies, conditionally
approved products should be fully reim-
bursed by insurers or other public funds
earmarked for the purpose.
This raises the second crucial issue of
balancingeconomic riskandbenefit.Med-Cell Stem Ceical product development is typically a
high-risk, high-reward venture. However,
under the conditional approvals scheme,
private companieswill be able to subsidize
their late-stage clinical testing through
reimbursements, as well as secondarily
through the development of any publicly
funded systems, such as outcome data
repositories, used in post-market efficacy
testing. In effect, Japan’s (mainly public-
sector) insurance payers are entering into
a partnership with a private-sector entity
during what is ordinarily the most costly
stage of product development. Given the
relative financial contributions in these
public–privatepartnerships, it seemsnatu-
ral that the public should be the dominant
partner, to prevent public risks from fueling
private profits.
There is no question that Japan’s poli-
cymakers have embarked on a funda-
mental effort to propel regenerative
medicine from the nation’s laboratory
benches to its hospital beds. But even
deregulation must have its limits. Health-
care markets are special in that they
are characterized by inelastic demand
and frequent reliance on credence goods,
and the evolution of pre-market re-
quirements, despite all the attendant
frustrations, has developed to provide
a scientific foundation to medicine
and thereby maximize patient welfare
and the common good. With bold mea-
sures such as these, Japan clearly hopes
to compete and succeed in the race to
build a regenerative medicine industry
by flattening a few hurdles. But as any
competitor should know, lowering the
bar does not make one leap any higher.
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